NO20072654L - Cancer behandling - Google Patents

Cancer behandling

Info

Publication number
NO20072654L
NO20072654L NO20072654A NO20072654A NO20072654L NO 20072654 L NO20072654 L NO 20072654L NO 20072654 A NO20072654 A NO 20072654A NO 20072654 A NO20072654 A NO 20072654A NO 20072654 L NO20072654 L NO 20072654L
Authority
NO
Norway
Prior art keywords
methods
cancer treatment
cancer cells
treatment
disaster
Prior art date
Application number
NO20072654A
Other languages
English (en)
Norwegian (no)
Inventor
Helene Heather Bendall
Gary T Elliott
Lorenzo M Leoni
Carol Christina Niemeyer
Pratik S Multani
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072654(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20072654L publication Critical patent/NO20072654L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20072654A 2004-11-05 2007-05-24 Cancer behandling NO20072654L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62519304P 2004-11-05 2004-11-05
US66022605P 2005-03-10 2005-03-10
PCT/US2005/040068 WO2006065392A2 (en) 2004-11-05 2005-11-04 Cancer treatments

Publications (1)

Publication Number Publication Date
NO20072654L true NO20072654L (no) 2007-07-25

Family

ID=36588320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072654A NO20072654L (no) 2004-11-05 2007-05-24 Cancer behandling

Country Status (12)

Country Link
US (2) US20060128777A1 (https=)
EP (1) EP1814544A4 (https=)
JP (1) JP2008519047A (https=)
CN (1) CN101933923A (https=)
AR (1) AR054094A1 (https=)
AU (1) AU2005317047A1 (https=)
CA (1) CA2585659A1 (https=)
CL (1) CL2009001721A1 (https=)
MX (1) MX2007005361A (https=)
NO (1) NO20072654L (https=)
TW (1) TW200621240A (https=)
WO (1) WO2006065392A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409227C1 (pt) 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20090075967A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ceftriaxone
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US8962614B2 (en) * 2008-04-17 2015-02-24 The Johns Hopkins University ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
MX2011005643A (es) * 2008-12-03 2011-09-27 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
ES2525257T3 (es) * 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク． ベンダムスチンの経口製剤
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
SMT201700043T1 (it) 2010-01-28 2017-03-08 Eagle Pharmaceuticals Inc Formulazioni di bendamustina
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
JO3587B1 (ar) * 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
KR20140064873A (ko) 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
JP6330118B2 (ja) * 2011-09-13 2018-05-30 ファーマサイクリックス エルエルシー ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
JP6250628B2 (ja) 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
CN104271135B (zh) 2012-03-20 2017-05-17 赛多斯有限责任公司 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
US10220051B2 (en) 2012-03-29 2019-03-05 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US8927516B2 (en) * 2012-03-29 2015-01-06 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
EP3052655B1 (en) 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
EP3116481A1 (en) * 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
DK0752248T3 (da) * 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0725642T3 (da) * 1993-10-27 2000-05-29 Upjohn Co Stabiliseret prostaglandin E1
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
GB9524334D0 (en) * 1995-11-28 1996-01-31 Philips Electronics Nv Mos transistor
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
CN1487936A (zh) * 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 具有改进吸收性能的药物组合物
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
CN1568166A (zh) * 2001-10-15 2005-01-19 荷姆泰克股份有限公司 预防再狭窄的涂层支架
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
EP1501565B1 (de) * 2002-05-09 2006-11-02 Hemoteq GmbH Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US6966329B2 (en) * 2003-01-27 2005-11-22 Hydraforce, Inc. Proportional pilot-operated flow control valve
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
CA2516191A1 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers

Also Published As

Publication number Publication date
AR054094A1 (es) 2007-06-06
US20090209606A1 (en) 2009-08-20
AU2005317047A1 (en) 2006-06-22
EP1814544A2 (en) 2007-08-08
WO2006065392A3 (en) 2006-12-21
CL2009001721A1 (es) 2010-02-19
WO2006065392A2 (en) 2006-06-22
EP1814544A4 (en) 2009-12-02
TW200621240A (en) 2006-07-01
JP2008519047A (ja) 2008-06-05
WO2006065392A8 (en) 2007-03-01
CN101933923A (zh) 2011-01-05
CA2585659A1 (en) 2006-06-22
MX2007005361A (es) 2008-01-11
US20060128777A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20072654L (no) Cancer behandling
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
NO20070782L (no) Tetrapeptidanaloger.
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
NO20055731L (no) Cannabinoide reseptorligander og deres anvendelse
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO20013155L (no) Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi
DK1761266T3 (da) Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
ATE363896T1 (de) Gegen missbrauch gesicherte darreichungsform
NO20051942D0 (no) Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
TW200616639A (en) Methods for treating a mammal before, during and after cardiac arrest
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application